Ketamine-Propofol vs Ketamine-Dexmedetomidine Combinations in Pediatric Patients Undergoing Burn Dressing Changes

From the • •.
Journal of burn care & research: official publication of the American Burn Association (Impact Factor: 1.43). 08/2012; 33(6). DOI: 10.1097/BCR.0b013e3182504316
Source: PubMed


The aim of this study was to compare ketamine-propofol (KP) and ketamine-dexmedetomidine (KD) combinations for deep sedation and analgesia during pediatric burn wound dressing changes. After obtaining approval from the University Ethics Committee, burn wound care or wound dressing changes were performed on 60 ASA physical status I and II inpatients aged between 8 and 60 months with second-degree burns ranging from 5 to 25% TBSA. After recording the demographic data, the heart rate, systolic arterial pressure, diastolic arterial pressure, peripheral oxygen saturation, respiratory rate, and Ramsey sedation scores were recorded for all patients before and during the procedure. Group KP (n = 30) received 1 mg kg-1 ketamine + 1 mg kg propofol and group KD (n = 30) received 1 mg kg ketamine + 0.5 μg kg-1 dexmedetomidine for induction. Additional propofol (1 mg kg) for group KP and additional dexmedetomidine (0.5 μg kg) for group KD were administered when required. No statistically significant differences in sedation scores and peripheral oxygen saturation and diastolic arterial pressure (P > .05) were found between the two groups. However, systolic blood pressure values in group KD showed a significant increase after induction (P < .05). The recovery time was longer in group KD than in group KP (P > .05). The respiratory rate was higher in group KD than in group KP beginning from the fifth minute of the procedure. A significant amount of respiratory depression and hypoxia was observed in group KP but not in KD (P < .05). Both the KP and KD combinations were effective for sedation and analgesia during dressing changes in the pediatric burn patients. The KD combination can be considered as an excellent alternative for pediatric wound dressing changes which does not result in respiratory depression.

Download full-text


Available from: Zeynep Tosun
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sedation for burn patients is provided by a variety of techniques determined usually by institutional preferences. The available pool of drugs has recently expanded to include dexmedetomidine (DEX), a α2-adrenergic receptor agonist with analgesic and sedative potential. Beneficial effects of DEX in burn patients have been described in many studies published over the last 5 years. The aim of this study is to perform a systematic review and meta-analysis of the available literature to determine the role of DEX for analgosedation of burn patients. We searched any article that matched the keywords "dexmedetomidine" and "burn", published before October 01, 2012. The methodological quality of studies was assessed using the recommendation of the Oxford Centre for Evidence Based Medicine (OCEBM). Our search yielded eleven total citations, of which four studies (266 patients) met the inclusion criteria of DEX for analgosedation in burn patients. There are no meta-analyses published that met our inclusion criteria. Even though there were only a small number of clinical trials available, the meta-analysis shows evidence for deeper and better sedation as well as for prevention of hypertension when using DEX as an adjunct during burn procedures. No evidence was found for reduced pain scores in this setting. The authors recommend the development of a prospective, randomized, controlled multicenter trial with an adequate number of patients to further elucidate the potentially beneficial effects of DEX for the management of burn patients.
    No preview · Article · Mar 2013 · Burns: journal of the International Society for Burn Injuries
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Duchenne muscular dystrophy (DMD) possesses many potential challenges for anesthetic care. Invasive and noninvasive procedures with corresponding sedation or general anesthesia are frequent and necessary for affected patients. There remains a need for a better agent or agents for procedural sedation in patients with comorbid diseases. This study prospectively evaluated a combination of ketamine with two different doses of dexmedetomidine for sedation during muscle biopsy in patients with DMD.Methods Dexmedetomidine 1.0 or 0.5 μg·kg−1 was administered as a loading dose over 3 min followed by a continuous infusion of 1.0 or 0.5 μg·kg·h−1. Ketamine (1 mg·kg−1) was administered along with the dexmedetomidine loading dose. As the procedure commenced, additional doses of ketamine (0.5 mg·kg−1) were administered as needed. Sedation scores, hemodynamic data, operative times, and recovery times were recorded.ResultsThe study cohort included a total of 53 bicep, deltoid, or anterior tibialis muscle biopsies in 19 boys including 24 in the dexmedetomidine 1.0 μg·kg−1 group and 29 in the dexmedetomidine 0.5 μg·kg−1 group. Mean age and weight were 9.7 ± 1.4 years and 33.3 ± 7.7 kg in the dexmedetomidine 1.0 μg·kg−1 group and 8.8 ± 1.8 years and 30.2 ± 10.8 kg in the dexmedetomidine 0.5 μg·kg−1 group. No significant changes in blood pressure were noted. A decrease in heart rate (HR) occurred after the loading dose of dexmedetomidine in both groups. The HR was significantly lower in the dexmedetomidine 1.0 μg·kg−1 group compared with the dexmedetomidine 0.5 μg·kg−1 group. Total recovery time to discharge was significantly shorter in the dexmedetomidine 0.5 μg·kg−1 group than the dexmedetomidine 1.0 μg·kg−1 group (146 ± 65 vs 174 ± 58 min; P = 0.03), although the total ketamine dose was significantly greater in the dexmedetomidine 0.5 μg·kg−1 group (3.7 ± 1.0 vs 2.0 ± 0.5 mg·kg−1; P < 0.01). There were no episodes of apnea or hypoventilation; however, a jaw thrust was needed in one patient in the dexmedetomidine 1.0 μg·kg−1group.Conclusion The combination of dexmedetomidine and ketamine is safe and effective for moderately painful procedures with limited respiratory and cardiovascular effects in a high-risk patient population. Dexmedetomidine 0.5 μg·kg−1 as a loading dose with ketamine followed by a continuous infusion of dexmedetomidine at 0.5 μg·kg−1·h−1 achieved an adequate sedation level with shorter total recovery times in the perioperative unit compared with a higher dose regimen of dexmedetomidine (1.0 μg·kg−1 loading dose followed by an infusion at 1.0 μg·kg−1·h−1).
    No preview · Article · Mar 2014 · Pediatric Anesthesia
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Ketamine and dexmedetomidine are increasingly used in combination in pediatric patients. This study examined the hypothesis that dexmedetomidine attenuated ketamine-induced neurotoxicity. Methods Neonatal rats were randomly divided into four groups (n=10, male 5, female 5). Group S+S received an equal volume of normal saline intraperitoneally and subcutaneously at an interval of 5min. Group K+S received an intraperitoneal injection of 75mg/kg ketamine followed by subcutaneous injection of normal saline 5min later. Group S+D were given subcutaneously 25g/kg dexmedetomidine 5min after injection of normal saline. Group K+D received a subcutaneous injection of 25g/kg dexmedetomidine 5min after ketamine injection. The above drugs were given once daily for 3days. Neuronal apoptosis in the CA1 region and the dentate gyrus of rats was examined by transferase dUTP nick end labeling (TUNEL) assays. Learning and memory abilities of 2-month old rats were examined by Morris water maze test. The results were analyzed by analysis of variance. ResultsThe percentage of TUNEL-positive cells in group K+S (CA1, 49.09.46 and dentate gyrus, 49.4 +/- 5.41) was markedly higher than that in group K+D (CA1, 37.2 +/- 5.54 and dentate gyrus, 35.2 +/- 5.06) (F=5.49, P<0.05 and F=13.51, P<0.001, respectively). Group K+S took significantly longer time and swimming distance to find the hidden platform on the fourth and fifth training days than group K+D (P<0.05). Moreover, group K+D spent considerably more time in the target quadrant than group K+S (P<0.05). Dexmedetomidine alone caused a small but statistically insignificant increase in neuronal apoptosis of the CA1 region and the dentate gyrus of neonatal rats compared with normal saline. Conclusion In conclusion, ketamine caused neuroapoptosis and impaired brain functions in the developing rat brain which can be effectively attenuated by dexmedetomidine. Dexmedetomidine alone was not neurotoxic to the developing brain.
    No preview · Article · Jul 2014 · Acta Anaesthesiologica Scandinavica
Show more